Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. 

Eisai to Make New Investment in Expansion of Global Packaging Facility at Hatfield Production Plant in U.K. (Jun 17, 2013)

Eisai Confirms Therapeutic Effects of Lenvatinib in Patients with Melanoma in Strategic Collaboration with Quintiles to Develop Eisai Anticancer Compounds (Jun 10, 2013)

Eisai Presents New Quality of Life Findings in Patients with Metastatic Breast Cancer from Halaven(R) (Eribulin) versus Capecitabine Study at 49th ASCO Annual Meeting (Jun 3, 2013)

Eisai Announces Launch of Antiepileptic Agent Inovelon(R) Tablets 100 mg, 200 mg in Japan (May 28, 2013)

Eisai Announces Preclinical Research Findings Suggesting Novel Infibitory Effect on Tumor Metastasis for Anticancer Agent Halaven(R) at AACR 104th Annual Meeting (Apr 10, 2013)

Eisai Co-establishes the Global Health Innovative Technology Fund (Apr 8, 2013)

Eisai Establishes Pharma Sales Subsidiary in Moscow Ahead of Planned Direct Sales Launch in Russia (Apr 5, 2013)

Eisai to Launch Botulinum Toxin Type B Neuromuscular-Blocking Agent Nerbloc(R) intramuscular Injection 2500 Units in Japan (Mar 26, 2013)

Eisai Recieves Manufacturing and Marketing Authorization for Antiepileptic Agent Inovelon(R) in Japan (Mar 25, 2013)

Eisai Announces Launch of Chocola BB(R) Sparkling + Fiber, Containing 5 Ingredients that Help Bring Out Beauty from Within (Feb 26, 2013)

Eisai Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum-Sensitive Ovarian Cancer (Jan 11, 2013)

Noblepharma and Eisai Announce Japan Lunch of Antineoplastic Agent Gliadel(R) 7.7 mg Implant (Jan 8, 2013)

Eisai Signs Agreement with Epizyme and Roche Molecular Systems to Develop Companion Diagnostic (Jan 8, 2013)